Tag Archives: weight-loss

Huge Study Finds Constellation of Health Benefits for Ozempic Beyond Weight Loss

Posted on by

In a ginormous new study, researchers have begun mapping the manifold health benefits of drugs like Ozempic and Wegovy beyond weight loss. 

In a ginormous new study, researchers have begun mapping the manifold health benefits of drugs like Ozempic and Wegovy beyond weight loss.

Published in the journal Nature Medicine, this new study led by Ziyad Al-Aly of the Veteran's Affairs health system in St. Louis tracked millions of diabetes patient outcomes over a period of 3.5 years.

Of those, over 215,000 had been prescribed a glucagon-like peptide-1 (GLP-1) agonist receptor — the class of drugs that includes Ozempic, Wegovy, Mounjaro, Zepbound, and others — and 1.7 million were on another form of blood sugar-lowering medicine.

Looking at other disorders in the data ranging from Parkinson's disease and Alzheimer's to kidney disease and opiate addiction, Al-Aly and his team found that those who were on GLP-1 medications saw significant improvement across a staggering range of health concerns — and far beyond anything clearly linked to weight or blood sugar.

Though many studies have found that these blockbuster drugs seem to be beneficial for specific disorders, "no one had comprehensively investigated the effectiveness and risks of GLP-1 receptor agonists across all possible health outcomes," the physician-scientist told Nature.

In particular, Al-Aly said that the drugs' impact on addiction disorders "stood out" to him, with 13 percent of the GLP-1 cohort who had issues with addiction seeing improvement — a finding that dovetails with other studies about these drugs and their effect on addiction.

Other apparent benefits were even harder to make sense of. Al-Aly and his team also discovered that psychotic disorder risk was lowered by 18 percent for the GLP-1 cohort, and the Alzheimer's risk was cut by 12 percent.

"Interestingly, GLP-1RA drugs act on receptors that are expressed in brain areas involved in impulse control, reward and addiction — potentially explaining their effectiveness in curbing appetite and addiction disorders," Al-Aly said in a statement published by the University of Washington, which was also involved in the study. "These drugs also reduce inflammation in the brain and result in weight loss; both these factors may improve brain health and explain the reduced risk of conditions like Alzheimer’s disease and dementia."

While those findings are indeed incredible, the researchers also found that other issues seemed to be exacerbated by taking GLP-1s. Along with an 11 percent increase in arthritis risk, the team found a whopping 146 percent increase in cases of pancreatitis — another discovery that complements prior research into the drugs' dark side.

Though that figure is pretty jarring, Al-Aly seemed to take it in stride.

"Given the drugs’ newness and skyrocketing popularity, it is important to systematically examine their effects on all body systems — leaving no stone unturned — to understand what they do and what they don’t do," he said in the UWash press release.

By looking so deeply into the drugs, these scientists are, as Al-Aly puts it, drawing a "comprehensive atlas mapping the associations" of GLP-1 drugs that looks into all of their effects on the body — an important quest as they continue to rise in popularity and usage.

More on GLP-1s: Woman Annoyed When She Gets on Wegovy and It Does Nothing

The post Huge Study Finds Constellation of Health Benefits for Ozempic Beyond Weight Loss appeared first on Futurism.

See more here:
Huge Study Finds Constellation of Health Benefits for Ozempic Beyond Weight Loss

Woman Annoyed When She Gets on Wegovy and It Does Nothing

Posted on by

For some, the issue with GLP-1 drugs like Wegovy isn't getting access to these game-changing medications, but having them not work.

The fever-pitch hype around GLP-1 drugs like Ozempic and Mounjaro makes them sound like game-changing medications, and for many they are — but for other patients, the experience is totally underwhelming.

In an interview with the Associated Press, 38-year-old Danielle Griffin said that although she was able to get a prescription for Novo Nordisk's weight loss shot Wegovy — and even got it covered by her insurance, which is still often a struggle — the medication just didn't work for her.

"I have been on Wegovy for a year and a half," Griffin said, "and have only lost 13 pounds."

Despite doing "everything right," including dieting, exercising, and drinking lots of water, she's had "no success" with the popular weight loss injectable.

"It’s discouraging," Giffin said.

While there's been scrutiny on a laundry list of side effects that can come with glucagon-like peptide-1 drugs, which seem to work by mimicking the body's feeling of fullness, non-responsiveness of this sort hasn't captured much attention.

Obesity experts told the AP, however, that up to 20 percent — or one in every five patients — may not lose weight on the drugs at all.

Dr. Fatima Cody Stanford, an obesity expert at Massachusetts General Hospital, told the news wire that because "different people have different responses," these drugs won't work the same for everyone who takes them.

From medications that stymie weight loss to differences in brain and gut chemistry, lots of factors influence how people metabolize GLP-1s, the Mass General doctor said.

"[Obesity] is a disease that stems from the brain," Stanford said. "The dysfunction may not be the same."

Endocrine specialist Jody Dushay of Boston's Beth Israel Deaconess Medical Center said that she's also seen people have issues losing weight with GLP-1s — though generally, she and her patients are able to tell whether they're going to work within a few weeks.

Between non-responsiveness and undesirable gastrointestinal side effects like vomiting, nausea, and diarrhea, those who run into issues with drugs like Wegovy often feel at wit's end, Dushay said. There are plenty of other options, however, including switching to a different GLP-1.

"I tell them: it's not game over," the endocrinologist said.

Indeed, Griffin told the AP that she eventually switched over to Zepbound, a similar drug made by Eli Lilly — and that within just three months, she'd lost seven pounds.

"I’m hoping it’s slow and steady," the woman said.

More on GLP-1s: The Diet Industry Is Reportedly in Total Meltdown Over GLP-1 Weight Loss Drugs

The post Woman Annoyed When She Gets on Wegovy and It Does Nothing appeared first on Futurism.

Read more:
Woman Annoyed When She Gets on Wegovy and It Does Nothing

Deranged Mayor Promises "No More Fat People" With Free Ozempic Shots

Posted on by

While seeking re-election, the mayor of Rio de Janeiro is making a huge campaign promise: free Ozempic for all.

While seeking re-election, the mayor of Rio de Janeiro is making a huge campaign promise: free Ozempic for all.

As Quartz reports, Rio Mayor Eduardo Paes said that he lost 66 pounds after taking the popular weight-loss injectable manufactured by Danish drugmaker Novo Nordisk.

"I took a lot of Ozempic, that little medicine that is helping everyone lose weight," Paes told Brazilian newspaper Extra, as translated by Quartz. "Its patent will expire next year, and it will be available as a generic and I will introduce it to the entire public health system."

As a note, the latter claim is not exactly true. Though there have been challenges to speed up the pace of generics in Brazil, the patent for semaglutide, the main ingredient in Ozempic and Wegovy, isn't slated to expire in the country until 2026.

After claiming he'd "introduce" the generic into the city's public health system without discussing how he would undertake such an endeavor as the leader of an individual municipality, the longtime Rio mayor then made an even bolder claim.

"Rio will be a city where there will be no more fat people," Paes declared. "Everyone will be taking Ozempic at family clinics."

Problematic fatphobia aside, Rio de Janeiro's population is a whopping 13.7 million people, making his claim a massive stretch.

Understandably, Paes' controversial comments opened him up to criticism from opponents in the mayoral election, which is set to occur on October 6.

Mayoral candidate Alexandre Ramagem, posted a carousel on his campaign's Instagram showing voters complaining online about lacking basic medical necessities in the face of Paes' comments. Fellow mayor hopeful Tarcísio Motta, meanwhile, said the comments were fatphobic and "disrespectful to the diversity of bodies" in Rio.

Hitting back, Paes insisted he isn't fatphobic and said he's only interested in the health of the city's populace.

"When the patent is broken, which should happen in 2025 or 2026, it will reduce the cost enormously," the longtime mayor said, referencing the 1,000 Brazilian Reals or roughly $182 it currently costs Brazilians to access the weight loss drug. "Why not make it available to the population?"

"We’re not going to give it away for vain reasons," he continued. "It’s not to make six-packs."

As usual, a politician is politicking — but in Rio, the personal seems to have become political.

More on Ozempic: People Are Apparently Microdosing Ozempic

The post Deranged Mayor Promises "No More Fat People" With Free Ozempic Shots appeared first on Futurism.

Read more here:
Deranged Mayor Promises "No More Fat People" With Free Ozempic Shots